Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation

PHASE3CompletedINTERVENTIONAL
Enrollment

411

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Chronic Idiopathic Constipation
Interventions
DRUG

Elobixibat 10 mg

10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.

Trial Locations (62)

Unknown

Genova Clinical Research, Inc., Tucson

Preferred Research Partners, Little Rock

Arkansas Gastroenterology, North Little Rock

Skyline Research, LLC, Cerritos

West Gastroenterology Associates, Los Angeles

Sacramento Research Medical Group, Sacramento

Stamford Therapeutics Consortium, Stamford

Zasa Clinical Research, Boynton Beach

Meridien Research, Bradenton

Pulmonary Associates of Brandon, Brandon

Health Care Family Rehab Corp., Hialeah

Medsearch Professional Group, Inc., Hialeah

The Community Research of South Florida, Hialeah

Center for Gastrointestinal Disorders, Hollywood

Nature Coast Clinical Research, LLC, Inverness

Health Awareness, Inc., Jupiter

Jupiter Research Inc., Jupiter

Advanced Pharma CR, LLC, Miami

Research Institute of South Florida, Miami

Palm Beach Research Center, West Palm Beach

Mount Vernon Clinical Research, Atlanta

Georgia Clinical Research, Snellville

Evanston Hospital, Evanston

Rockford Gastroenterology Associates, Ltd., Rockford

MediSphere Medical Research Center, LLC, Evansville

Heartland Research Associates, LLC, Augusta

Heartland Research Associates, LLC, Wichita

Louisiana Research Center, LLC, Shreveport

Boston Clinical Trials, Boston

Beacon Clinical Research, LLC, Brockton

Quality Clinical Research, Inc., Omaha

Advanced Biomedical Research of America, Las Vegas

ActivMed Practices and Research, Inc., Newington

Long Island Gastrointestinal Research Group, Great Neck

Carolina Digestive Health Associates, PA, Concord

Cumberland Research Associates, LLC, Fayetteville

PharmQuest, LLC, Greensboro

Peters Medical Research, LLC, High Point

TriHealth, Inc., Cincinnati

Clinical Research Associates, LLC, Oklahoma City

Sunstone Medical Research, LLC, Medford

Family Medical Associates, Levittown

Clinical Trials Research Services, LLC, Pittsburgh

Anderson Gastroenterology Associates, Anderson

ClinSearch, Chattanooga

Memphis Gastroenterology Group, PC, Germantown

Associates in Gastroenterology, LLC, Hermitage

HCCA Clinical Research Solutions, Jackson

KRK Medical Research, Dallas

Pioneer Research Solutions, Inc., Houston

Pioneer Research Solutions, Inc., Sugar Land

Gastroenterology Associates of Tidewater, Chesapeake

Northwest Gastroenterology Associates, Bellevue

Cliniques Universitaires Saint Luc (there may be other sites in this country), Brussels

Prime Health Clinical Research Organization (there may be other sites in this country), Toronto

Gastroenterologie, s. r. o. (there may be other sites in this country), Hradec Králové

Pannónia Magánorvosi Centrum Kft. (there may be other sites in this country), Budapest

SPZOZ Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi (there may be other sites in this country), Lódz

KM Management sro (there may be other sites in this country), Nitra

Louise Lelpoldt Medical Centre (there may be other sites in this country), Bellville

Uppsala Akademiska Sjukhus (there may be other sites in this country), Uppsala

Synexus Merseyside Clinical Research Centre (there may be other sites in this country), Liverpool

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT01895543 - Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation | Biotech Hunter | Biotech Hunter